Jyong Biotech (NASDAQ:MENS) Stock Price Down 2.2% – What’s Next?

Jyong Biotech Ltd. (NASDAQ:MENS) fell 2.2% during trading on Wednesday. The stock traded as low as $1.66 and last traded at $1.74. Approximately 83,211 shares changed hands during mid-day trading, an increase of 88% from the average session volume of 44,258 shares. The stock had previously closed at $1.78.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Wednesday, August 19th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Jyong Biotech currently has an average rating of “Sell”.

Jyong Biotech Price Performance

The company’s fifty day moving average is $2.05 and its 200-day moving average is $2.14.

Hedge Funds Weigh In On Jyong Biotech

A hedge fund recently bought a new position in Jyong Biotech stock. StoneX Group Inc. acquired a new position in Jyong Biotech Ltd. (NASDAQ:MENS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 15,248 shares of the company’s stock, valued at approximately $33,000.

About Jyong Biotech

Jyong Biotech is a China-based biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for urological diseases. The company’s research approach includes developing drug candidates derived from natural products and traditional Chinese medicine.

Its development pipeline is centered on treatments for conditions affecting the urinary and male reproductive systems, including benign prostatic hyperplasia. Jyong Biotech is a clinical-stage company, and its primary activities include pharmaceutical research, clinical development and the evaluation of potential products for future commercialization.

The company serves the pharmaceutical and healthcare markets in China and is seeking to develop therapies with broader commercial potential.